{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T21:19:18Z","timestamp":1721855958203},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,17]]},"DOI":"10.7759\/cureus.17268","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T07:34:00Z","timestamp":1629272040000},"source":"Crossref","is-referenced-by-count":3,"title":["Real-Life Benefit of Omalizumab in Improving Control of Bronchial Asthma During COVID-19 Pandemic"],"prefix":"10.7759","author":[{"given":"Polliana Mihaela","family":"Leru","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vlad Florin","family":"Anton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)33005-3","article-title":"Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma","volume":"395","author":"Peters MC","year":"2020","unstructured":"Peters MC, Wenzel SE. Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma. Lancet. 2020, 395:371-383. 10.1016\/S0140-6736(19)33005-3","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.11.639","article-title":"Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program","volume":"119","author":"Moore WC","year":"2007","unstructured":"Moore WC, Bleecker ER, Curran-Everett D, et al.. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol. 2007, 119:405-413. 10.1016\/j.jaci.2006.11.639","journal-title":"J Allergy Clin Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1159\/000338998","article-title":"The cost of persistent asthma in Europe: an international population-based study in adults","volume":"160","author":"Accordini S","year":"2013","unstructured":"Accordini S, Corsico AG, Braggion M, et al.. The cost of persistent asthma in Europe: an international population-based study in adults. Int Arch Allergy Immunol. 2013, 160:93-101. 10.1159\/000338998","journal-title":"Int Arch Allergy Immunol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2174\/1573398X17666210119105547","article-title":"Biomarkers in asthma - interpretation and utility in current asthma management","volume":"17","author":"Leru PM","year":"2021","unstructured":"Leru PM. Biomarkers in asthma - interpretation and utility in current asthma management. Curr Respir Med Rev. 2021, 17:10.2174\/1573398X17666210119105547","journal-title":"Curr Respir Med Rev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.12714","article-title":"Atopy and lifestyle survey of allergic patients from urban environment in Romania: preliminary data from an interactive qualifying project","volume":"13","author":"Leru PM","year":"2021","unstructured":"Leru PM, Kay D, Kelly J, Tuong T, Schaeffer T, Addison B, Neamtu R. Atopy and lifestyle survey of allergic patients from urban environment in Romania: preliminary data from an interactive qualifying project. Cureus. 2021, 13:e12714. 10.7759\/cureus.12714","journal-title":"Cureus"},{"key":"ref6","unstructured":"Global Initiative for Asthma (GINA). Difficult-to-treat and severe asthma in adolescent and adult patients, diagnosis and management guideline. (2019). http.\/\/www.ginasthma.org."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/all.14024","article-title":"Biologicals in allergic diseases and asthma: toward personalized medicine and precision health: highlights of the 3rd EAACI Master Class on Biologicals, San Lorenzo de El Escorial, Madrid, 2019","volume":"75","author":"Palomares O","year":"2020","unstructured":"Palomares O, Untersmayr E, Gutermuth J, et al.. Biologicals in allergic diseases and asthma: toward personalized medicine and precision health: highlights of the 3rd EAACI Master Class on Biologicals, San Lorenzo de El Escorial, Madrid, 2019. Allergy. 2020, 75:936-940. 10.1111\/all.14024","journal-title":"Allergy"},{"key":"ref8","unstructured":"British Thoracic Society. Advice for healthcare professionals treating people with asthma (adults) in relation to COVID-19. (2020). https.\/\/www.brit-thoracic.org.uk\/covid-19\/covid-19-information-for-the-respiratory-community\/."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/all.14453","article-title":"COVID-19 pandemic: practical considerations on the organization of an allergy clinic - an EAACI\/ARIA position paper","volume":"76","author":"Pfaar O","year":"2021","unstructured":"Pfaar O, Klimek L, Jutel M, et al.. COVID-19 pandemic: practical considerations on the organization of an allergy clinic - an EAACI\/ARIA position paper. Allergy. 2021, 76:648-676. 10.1111\/all.14453","journal-title":"Allergy"},{"key":"ref10","unstructured":"National Institute for Health and Care Excellene (NICE). COVID-19 rapid guideline. severe asthma. NICE guideline. (2020). http:\/\/www.nice.org.uk\/guidance\/ng166."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/1753466618810192","article-title":"Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness","volume":"12","author":"Pelaia C","year":"2018","unstructured":"Pelaia C, Calabrese C, Terracciano R, de Blasio F, Vatrella A, Pelaia G. Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness. Ther Adv Respir Dis. 2018, 12:1753466618810192. 10.1177\/1753466618810192","journal-title":"Ther Adv Respir Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201810-1944CI","article-title":"Role of biologics in asthma","volume":"199","author":"McGregor MC","year":"2019","unstructured":"McGregor MC, Krings JG, Nair P, Castro M. Role of biologics in asthma. Am J Respir Crit Care Med. 2019, 199:433-445. 10.1164\/rccm.201810-1944CI","journal-title":"Am J Respir Crit Care Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2014.03.010","article-title":"Omalizumab in asthma: an update on recent developments","volume":"2","author":"Humbert M","year":"2014","unstructured":"Humbert M, Busse W, Hanania NA, Lowe PJ, Canvin J, Erpenbeck VJ, Holgate S. Omalizumab in asthma: an update on recent developments. J Allergy Clin Immunol Pract. 2014, 2:525.e1-36.e1. 10.1016\/j.jaip.2014.03.010","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-017-0206-9","article-title":"4-Month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry","volume":"13","author":"Snelder SM","year":"2017","unstructured":"Snelder SM, Weersink EJ, Braunstahl GJ. 4-Month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry. Allergy Asthma Clin Immunol. 2017, 13:34. 10.1186\/s13223-017-0206-9","journal-title":"Allergy Asthma Clin Immunol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S112208","article-title":"A review of omalizumab for the management of severe asthma","volume":"10","author":"Lin CH","year":"2016","unstructured":"Lin CH, Cheng SL. A review of omalizumab for the management of severe asthma. Drug Des Devel Ther. 2016, 10:2369-2378. 10.2147\/DDDT.S112208","journal-title":"Drug Des Devel Ther"},{"key":"ref16","doi-asserted-by":"crossref","DOI":"10.7326\/0003-4819-154-9-201105030-00002","article-title":"Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial","volume":"154","author":"Hanania NA","year":"2011","unstructured":"Hanania NA, Alpan O, Hamilos DL, et al.. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011, 154:573-582.","journal-title":"Ann Intern Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/all.14425","article-title":"EAACI biologicals guidelines - recommendations for severe asthma","volume":"76","author":"Agache I","year":"2021","unstructured":"Agache I, Akdis CA, Akdis M, et al.. EAACI biologicals guidelines - recommendations for severe asthma. Allergy. 2021, 76:14-44. 10.1111\/all.14425","journal-title":"Allergy"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1515\/rjim-2015-0015","article-title":"Romanian allergology in the actual European context","volume":"53","author":"Leru PM","year":"2015","unstructured":"Leru PM, Deleanu DM. Romanian allergology in the actual European context. Rom J Intern Med. 2015, 53:111-117. 10.1515\/rjim-2015-0015","journal-title":"Rom J Intern Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/67536-real-life-benefit-of-omalizumab-in-improving-control-of-bronchial-asthma-during-covid-19-pandemic","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:33:49Z","timestamp":1707507229000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/67536-real-life-benefit-of-omalizumab-in-improving-control-of-bronchial-asthma-during-covid-19-pandemic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,17]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.17268","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8,17]]}}}